Cetera Advisors LLC Nektar Therapeutics Transaction History

Cetera Advisors LLC

8 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2024 May 14, 2024	SELL	$0.49 - $0.96 $147 - $288	-300 Reduced 2.44%	12,000 $11,000
Q4 2023 Feb 13, 2024	SELL	$0.42 - $0.57 $168 - $227	-400 Reduced 3.15%	12,300 $6,000
Q3 2023 Nov 14, 2023	SELL	$0.51 - $1.05 $2,335 - $4,809	-4,580 Reduced 26.5%	12,700 $7,000
Q2 2023 Aug 09, 2023	SELL	$0.53 - $1.03 $39 - $77	-75 Reduced 0.43%	17,280 $10,000
Q1 2023 May 15, 2023	SELL	$0.64 - $3.15 $384 - $1,890	-600 Reduced 3.34%	17,355 $12,000
Q4 2022 Feb 14, 2023	SELL	$2.03 - $4.28 $608 - $1,284	-300 Reduced 1.64%	17,955 $40,000
Q1 2022 May 12, 2022	BUY	$4.16 - $13.72 $13,000 - $42,875	3,125 Added 20.65%	18,255 $98,000
Q4 2021 Feb 14, 2022	BUY	$10.83 - $18.41 $163,857 - $278,543	15,130 New	15,130 $204,000

152

131M

92.7K

4.9K

Ticker NKTR
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 187,404,992
Market Cap $174M
Description
Nektar Therapeutics, a biopharmaceutical company, focuses on discovering and developing medicines in areas of unmet medical need in the United States and internationally. The company's products include Bempegaldesleukin, a CD122-preferential interleukin-2 (IL-2) pathway agonist, which is in phase 3 clinical trial to treat metastatic melanoma, re...

Get notified when there are updates to the investment portfolio of Cetera Advisors LLC, based on Form 13F filings with the SEC.

Stay updated on Cetera Advisors LLC with notifications on news.